Next Article in Journal
Kaposi’s Sarcoma-Associated Herpesvirus and Host Interaction by the Complement System
Next Article in Special Issue
Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
Previous Article in Journal
A Host-Specific Blocking Primer Combined with Optimal DNA Extraction Improves the Detection Capability of a Metabarcoding Protocol for Canine Vector-Borne Bacteria
Previous Article in Special Issue
Streptococcus pneumoniae Nasopharyngeal Carriage among PCV-10-Vaccinated HIV-1-Infected Children with Maintained Serological Memory in Ethiopia
Open AccessReview

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population

1
Department of Vaccine Preventable Diseases, Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, 0213 Oslo, Norway
2
Department of Bacteria, Parasites and Fungi, Statens Serum Institute, 2300 Copenhagen, Denmark
3
Infectious Disease Epidemiology & Prevention, Statens Serum Institute, 2300 Copenhagen, Denmark
4
Unit for Vaccination Programmes, Public Health Agency of Sweden, 171 82 Solna, Sweden
*
Author to whom correspondence should be addressed.
Pathogens 2020, 9(4), 259; https://doi.org/10.3390/pathogens9040259
Received: 6 March 2020 / Revised: 24 March 2020 / Accepted: 1 April 2020 / Published: 3 April 2020
(This article belongs to the Special Issue Development of Pneumococcal Vaccines for the World)
Adult vaccination is high on the agenda in many countries. Two different vaccines are available for the prevention of pneumococcal disease in adults: a 23-valent polysaccharide vaccine (PPV23), and a 13-valent conjugated vaccine (PCV13). The objective of this review is to update the evidence base for vaccine efficacy and effectiveness of PPV23 and PCV13 against invasive pneumococcal disease and pneumonia among an unselected elderly population. We systematically searched for clinical trials and observational studies published between January 1 2016 and April 17 2019 in Pubmed, Embase, Cinahl, Web of Science, Epistemonikos and Cochrane databases. Risk of bias was assessed using Cochrane Risk of Bias tool for and the Newcastle–Ottawa Scale. Results were stratified by vaccine type and outcome. We identified nine studies on PCV13 and six on PPV23. No new randomized clinical trials were identified. Due to different outcomes, it was not possible to do a meta-analysis. New high-quality observational studies indicate protective vaccine effectiveness for both vaccines against vaccine type pneumonia. Our estimates for the protective vaccine efficacy and effectiveness (VE) of PPV23 on pneumonia and pneumococcal pneumonia overlap with results from previously published reviews. Some of the results indicate that the effectiveness of the PPV23 is best in younger age groups, and that it decreases over time. View Full-Text
Keywords: pneumococcal vaccines; review; invasive pneumococcal disease; pneumonia; elderly pneumococcal vaccines; review; invasive pneumococcal disease; pneumonia; elderly
Show Figures

Figure 1

MDPI and ACS Style

Berild, J.D.; Winje, B.A.; Vestrheim, D.F.; Slotved, H.-C.; Valentiner-Branth, P.; Roth, A.; Storsäter, J. A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population. Pathogens 2020, 9, 259.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop